Advances in Multimodal Management of Primary and Secondary Liver Tumors

Primary and secondary liver tumors represent a heterogeneous group of malignancies and a major challenge in contemporary oncology. Primary liver cancers include hepatocellular carcinoma, intrahepatic cholangiocarcinoma, combined hepatocellular-cholangiocarcinoma, and rarer hepatic malignancies, while secondary liver tumors arise from a broad spectrum of primary cancers, most prominently colorectal cancer, but also neuroendocrine, pancreatic, gastric, breast, melanoma, and other malignancies.Their management has evolved substantially beyond traditional disease-specific treatment algorithms toward increasingly integrated and individualized strategies. Liver resection and transplantation remain potentially curative options in selected patients, while advances in minimally invasive surgery, locoregional treatments, systemic therapies, immunotherapy, molecularly targeted agents, and precision oncology are progressively expanding therapeutic opportunities.The traditional boundaries between resectable and unresectable disease are consequently becoming more dynamic. Modern systemic and locoregional treatments may enable downstaging and conversion to surgery, while innovative surgical strategies can extend resectability in patients with complex tumor burden. These developments emphasize the importance of multidisciplinary treatment planning based on tumor biology, anatomical distribution, liver function, molecular characteristics, and response to therapy.This Research Topic aims to provide a comprehensive and multidisciplinary overview of current and emerging strategies for the treatment of primary and secondary liver tumors, focusing on the integration of surgery, transplantation, locoregional therapies, systemic treatments, immunotherapy, and precision oncology.Particular attention will be devoted to treatment sequencing, conversion and downstaging strategies, evolving criteria for resectability and transplant eligibility, and biologically driven patient selection. The Topic will explore how advances in systemic and locoregional therapies can interact with modern surgical approaches to increase opportunities for potentially curative treatment.Ultimately, this collection aims to bridge hepatobiliary surgery, transplant oncology, medical oncology, interventional radiology, radiation oncology, and translational research.We welcome Original Research, Reviews, Systematic Reviews, Clinical Trials, and other relevant contributions addressing:• Primary liver malignancies, including hepatocellular carcinoma, intrahepatic cholangiocarcinoma, combined HCC-CCA, and rare primary hepatic tumors.• Secondary liver tumors, including colorectal liver metastases and metastases from neuroendocrine, pancreatic, gastric, breast, melanoma, and other malignancies.• Innovative liver surgery and transplant oncology, including minimally invasive and robotic surgery, parenchymal-sparing approaches, vascular reconstruction, staged procedures, transplantation, and strategies for initially unresectable disease.• Multimodal treatment and therapeutic sequencing, including neoadjuvant, adjuvant, conversion and downstaging strategies and the integration of systemic therapy, immunotherapy, targeted therapy, ablation, TACE, radioembolization, and radiotherapy.• Precision and translational oncology, including biomarkers, molecular profiling, liquid biopsy, advanced imaging, radiomics, and artificial intelligence for patient selection, prediction of treatment response, recurrence risk, and personalized therapeutic decision-making.Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal. Topic editors: Maurizio Romano, Alessandro Beleù, Michele Finotti, Leo Licari Source: https://www.frontiersin.org/research-topics/86309/advances-in-multimodal-management-of-primary-and-secondary-liver-tumors